Electronic Supplementary Material (ESI) for MedChemComm. This journal is © The Royal Society of Chemistry 2016

Supporting information

For

Development of novel bis-naphthalimide derivatives and their anticancer properties

Rui-Xue Rong,^{*a,b*} Qian Sun,^{*a*} Cui-Lan Ma,^{*a*} Bin Chen,^{*b*} Wen-Ying Wang,^{*a*} Zhong-Ao Wang,^{*b*} Ke-Rang Wang,^{*a*}* Zhi-Ran Cao, ^{*b*}* Xiao-Liu Li^{*a*}*

^{*a*} Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Key Laboratory of Chemical Biology of Hebei Province, College of Chemistry and Environmental Science, Hebei University, Baoding 071002, China. E-mail: <u>kerangwang@hbu.edu.cn</u>; <u>lixl@hbu.cn</u>. Tel: (+86)-312-5971116.

^b Department of Immunology, School of Medical Science, Hebei University, Baoding, P. R. China. E-mail: caozhiran@163.com.



Fig. S1 ¹H NMR (600 MHz, CDCl₃) of compound M1.



Fig. S2 ¹³C NMR (150 MHz, CDCl₃) of compound M1.



Fig. S3 MS (ESI) of compound M1.



Fig. S4 ¹H NMR (600 MHz, CDCl₃) of compound **N1**.



Fig. S5 ¹³C NMR (150 MHz, CDCl₃) of compound N1.

Mass Spectrum SmartFormula Report





Fig. S6 HRMS (ESI) of compound N1.



Fig. S7 ¹H NMR (600 MHz, CDCl₃) of compound N2.



Fig. S8 ¹³C NMR (150 MHz, CDCl₃) of compound N2.



Fig. S9 HRMS (ESI) of compound N2.



Fig. S10 ¹H NMR (600 MHz, DMSO-d₆ + D_2O) of compound **N3**.



Fig. S11 ¹³C NMR (150 MHz, DMSO-d₆ + D_2O) of compound **N3**.

Mass Spectrum SmartFormula Report

Analysis Info Acquisition Date 2013/10/12 15:26:19 Analysis Name D:\Data\20131012\Q7-ESI-POS-MSMS_000002.d Method 20130927 Operator Sample Name Instrument apex-Ultra Comment Acquisition Parameter Source No. of Cell Fills End Plate No. of Laser Shots Laser Power ESI Polarity Positive 20 51.0 % Averaged Scans Broadband Low Mass Broadband High Mass Acquisition Mode 1 . 3500.0 V 100.3 m/z MALDI Plate 300.0 V 4000.0 V 20.0 V 180.0 °C 4.0 L/min Capillary Entrance Skimmer 1 800.0 m/z Single MS 2000.0 µm Imaging Spot Diameter Pulse Program Source Accumulation basic 0.0 sec Drying Gas Temperature Drying Gas Flow Rate Tue Oct 8 03:08:56 2013 Calibration Date Data Acquisition Size Apodization 131072 Sine-Bell Multiplication Ion Accumulation Time Flight Time to Acq. Cell 0.0 sec Nebulizer Gas Flow Rate 1.0 L/min 0.0 sec +MS Intens x107







Fig. S13 ¹H NMR (600 MHz, DMSO- $d_6 + D_2O$) of compound N4.



Fig. S14 ¹³C NMR (150 MHz, DMSO-d₆ + D_2O) of compound N4.



Fig. S15 HRMS (ESI) of compound N4.



Fig. S16 ¹H NMR (600 MHz, DMSO-d₆ + D_2O) of compound **N5**.



Fig. S17 13 C NMR (150 MHz, DMSO-d₆ + D₂O) of compound N5.

Mass Spectrum SmartFormula Report





Fig. S18 HRMS (ESI) of compound N5.



Fig. S19 ¹H NMR (600 MHz, DMSO- $d_6 + D_2O$) of compound N6.



Fig. S20 ¹H NMR (600 MHz, DMSO-d₆ + D_2O) of compound **N6**.



Fig. S21 HRMS (ESI) of compound N6.



Fig. S22 UV-Vis spectra of compound NI1 (1×10^{-5} M) binding with Ct-DNA in phosphate buffer (10 mM, pH 7.4, 50 mM NaCl).



Fig. S23 Compound **NI1** induced lysosomal membrance permeabilization (LMP). Hela cells were stained with Annexin V-TITC. Numbers indicate the percentage of cells with Annexin V-TITC fluorescence.



Fig. S24 Inhibition of cell cycle process in Hela cellstreated with Amonafide for 48 h. Cell cycle distribution was analyzed by flow cytometry.

Table S1. Quantitative determination of hematoxic effects of compound **NI1** on the numbers of platelets (PLT), red blood cells (RBC) and white blood cells (WBC) in healthy mice when administered i.v. with different doses (5 mg/kg, 10 mg/kg and 20 mg/kg). Analyses were performed at 24 h, 48 h and 96 h following administration.

	Doses (mg/kg)	PLT (10 ⁹ /μL)	RBC (10 ¹² /µL)	WBC (10 ⁹ /µL)
Control		296.75±9.18	6.24±0.18	3.62±0.04
24 h	5	284.25±4.92*	6.34±0.05	3.48±0.24
	10	288.75±4.65	5.99±0.13	3.35±0.09
	20	299±6.48	5.8±0.46*	3.71±0.28
48 h	5	343.75±7.14*	6.1±0.25	3.71±0.28
	10	259.5±2.38*	6.19±0.96	2.03±0.09*
	20	407.75±23.16*	6.8±0.3	2.8±0.12*
96 h	5	343.5±6.56*	6.27±0.1	3.05±0.04*
	10	384.75±9.74*	6.2±1.4	3.14±0.17*
	20	364.5±6.61*	6.18±0.63	2.43±0.09*

Statistical significance (control versus treatment) was assessed using the Mean-Whitney U-test: * = p < 0.05.

Table S2. Quantitative determination of cardiotoxic effects of compound **NI1** on the levels of aspartate transaminase (AST), creatine kinase (CK) and lactate dehydrogenase (LDH) in healthy mice when administered i.v. with different doses (5 mg/kg, 10 mg/kg and 20 mg/kg). Analyses were performed at 24 h, 48 h and 96 h following administration.

	Doses (mg/kg)	AST (U/L)	LDH (U/L)	CK (U/L)
Control		159.83±9.82	861.5±90.78	1342.5±60.64
24 h	5	175.13±5.91	958.80±9.92	1628.2±111.51
	10	311.9±6.87*	1778.2±72.29*	1832.0±109.12*
	20	356.87±38.79*	1805.9±87.32*	1799.9±305.68
48 h	5	123.97±7.20*	1109.3±59.21*	1292.1±60.21
	10	139.73±8.93*	985.3±78.63	1196.7±37.4
	20	146.8±9.44	947.63±44.87	2035.3±45.66*
96 h	5	146.33±3.22	1146.2±40.06*	1648.8±51.51*
	10	163.37±15.2	1213.5±104.36*	2155.3±63.85*
	20	166.5±11.21	999.13±70.76	1483.7±58.42*

Statistical significance (control versus treatment) was assessed using the Mean-Whitney U-test: * = p < 0.05.